Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk Insights From the FOURIER Trial

Creative Commons License

O'Donoghue M. L., Fazio S., Giugliano R. P., Stroes E. S. G., Kanevsky E., Gouni-Berthold I., ...Daha Fazla

CIRCULATION, cilt.139, sa.12, ss.1483-1492, 2019 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 139 Sayı: 12
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1161/circulationaha.118.037184
  • Dergi Adı: CIRCULATION
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1483-1492
  • Hacettepe Üniversitesi Adresli: Evet

Özet

BACKGROUND: Lipoprotein(a) [Lp(a)] may play a causal role in atherosclerosis. PCSK9 (proprotein convertase subtilisin/kexin 9) inhibitors have been shown to significantly reduce plasma Lp(a) concentration. However, the relationship between Lp(a) levels, PCSK9 inhibition, and cardiovascular risk reduction remains undefined.